The firm’s unlisted high-conviction equities strategy is more than 44 per cent invested in healthcare stocks. The biotech has ...

Biotechnology firm Opthea has warned investors its solvency is in question after the failure of a major clinical trial into ...

The hedge fund run by veteran stockpicker Phil King has told investors that the eye treatment play is worth 20¢ per share. It ...

Opthea (NASDAQ:OPT – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a research note issued on Tuesday, Marketbeat.

The ASX All Ords dividend stock has come under heavy selling pressure in 2025. It’s now trading on a fully franked 8% ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

Trading in shares of Opthea remains halted in the U.S. and Australia after the clinical-stage biopharmaceutical company said its lead product candidate, sozinibercept, failed in a late-stage study in ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

A failed clinical trial has rattled investors. The post Amid fears of collapse, what's happening with Opthea ASX shares today ...

Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...

Jefferies double downgraded Opthea (OPT) to Underperform from Buy with a price target of $1, down from $8, after the company announced that its ...